- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05125133
Evaluation of Insecticide-treated Eave Nets and Window Screens for Malaria Control in Tanzania. (ITENs)
A Household Randomized Control Trial of Insecticide-treated Eave Nets and Window Screens for Malaria Control in Chalinze District, Tanzania.
This is a household randomized trial of a new tool for house modification, Insecticide-Treated Eave nets (ITENs) in combination with insecticide-treated window screens (ITWS), coated with a dual active ingredient (dual AI): Deltamethrin at 3g AI/kg, which corresponds to 144 mg/m² and PBO synergist at 10g/kg which corresponds to 480 mg/m², as used in the so-called dual-AI LLIN or "resistance breaking" nets for resistance malaria vector control.
Four hundred and fifty (450) households with intact walls, opened eaves, and those without screens or nets on the windows in Chalinze district, Tanzania will be eligible and only recruited upon written informed consent. The households will be randomly allocated into two arms: one with ITENs and ITWS installed and the other without.
The primary outcome will be malaria parasite detection in household residents aged over 6 months old using a quantitative Polymerase Chain Reaction (qPCR) at approximately 12 months post-installation, coinciding with the long rainy season.
Study Overview
Detailed Description
In Tanzania, long-lasting insecticidal nets (LLINs) contributed to the high reduction of malaria in the last decade. However, malaria reduction in Tanzania is threatened due to increasing insecticidal resistance of malaria vectors, low access to LLIN, LLINs not lasting up to three years, and net usage compliance. Therefore, it is evident that an additional cost-effective vector control tool is required that may confer protection against resistant malaria vectors, protect every member of the household, requires little or less compliance to use after distribution, and lasts longer.
The proposed additional vector control tool for trial is the Insecticide-Treated Eave nets (ITENs) in combination with Insecticide Treated Window screens (ITWS) for house modification. The tool is coated with a dual active ingredient (dual AI): Deltamethrin at 3g AI/kg, which corresponds to 144 mg/m², and PBO synergist at 10g/kg which corresponds to 480 mg/m², which are coated at the same concentration in insecticide-treated nets that are already in use in the population to control pyrethroid-resistant mosquitoes. These can protect everyone in the house by blocking mosquito entry and killing mosquitos that contact them to protect everyone in the community.
In this trial, 450 households will be randomly allocated into two arms. One arm with ITENs & ITWS installed and the other without to serve as the control arm. The 450 households are recruited and assigned codes during baseline data collection. The assigned codes are randomized to either of the two arms by simple randomization in STATA and stratified by sub-village.
Approximately 6 months and 12 months post-installation, coinciding with the rainy seasons, clinical officers will screen for malaria parasites in household residents of over 6 months old (it is estimated that 4.4 persons reside in each household, thus approx. 1,800 persons will be screened for malaria per survey) in both arms and confirmation of malaria parasite will be done using qPCR analysis as the primary assessment of the primary outcome. As a point of care, SD Bioline Malaria Ag Pf/Pan rapid diagnostic test (RDT) as per Tanzanian guidelines will also be conducted on all household residents. Any participant (s) with an axillary temperature of 37.5 degrees (fever) and that test positive using mRDT will be considered as a clinical malaria case. All malaria-positive participants will be treated using free Artemether Lumefantrine (ALu). This drug is approved by the national guideline for the treatment of uncomplicated malaria.
Other secondary objectives are:
- To evaluate malaria prevalence in households with ITENs & ITWS and those without at approximately 6 months post-installation, coinciding with the short rainy season.
- To determine the prevalence of clinical malaria defined by an axillary temperature of 37.5 degrees and above (fever) and mRDT malaria positive cases at approximately 6 months and 12 months post-installation, coinciding with the rainy seasons.
- To investigate the effect of ITENs and ITWS on the density of malaria vectors and nuisance (Culex quinquefasciatus) mosquitoes in the community at approximately 6 months and 12 months post-installation, coinciding with the rainy seasons using Centres for Disease Control (CDC) light traps.
- To assess the number of fabric in meters and time of installing the intervention (feasibility of scaling-up ITENs and ITWS use) in local houses in the field during installation.
- To assess the adverse effects of ITENs and ITWS in the community.
- To determine the attrition and fabric integrity of ITENs and ITWS in the field post 6 months and 12 months of installation.
- To determine the mortality induced by (bioefficacy) ITENs and ITWS on laboratory-reared mosquitoes post 12 months of installation.
- To determine the insecticide retainment of ITENs and ITWS post 12 months of installation.
- To assess the acceptability of ITENs and ITWS to the local community post 6 months and 12 months of installation.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Zawadi Mboma, PhD
- Phone Number: +255 787 428218
- Email: zmageni@ihi.or.tz
Study Contact Backup
- Name: Rose Philipo, MSc
- Phone Number: +255 714583404
- Email: rphilipo@ihi.or.tz
Study Locations
-
-
-
Bagamoyo, Tanzania
- Recruiting
- Vector Control Product Testing Unit Facility
-
Contact:
- Rose Philipo, MSc
- Phone Number: +255 714583404
- Email: rphilipo@ihi.or.tz
-
Principal Investigator:
- Zawadi Mboma, PhD
-
Sub-Investigator:
- Olukayode Odufuwa, MSc
-
Sub-Investigator:
- Sarah Moore, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Residents of study households' members.
Exclusion Criteria:
- None residence.
- Pregnant women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: ITENs + ITWS
Deltamethrin at 3g AI/kg, which corresponds to 144 mg/m², and PBO synergist at 10g/kg which corresponds to 480 mg/m² are coated in ITENs and ITWS nets that will be installed to cover opened eaves and windows.
This was manufactured by Moon Netting FZCO, United Arab Emirates.
|
A dual active ingredient (dual AI) Insecticide-Treated Eave nets (ITENs) in combination with Insecticide Treated Window screens (ITWS) for house modification.
|
|
No Intervention: Negative arm
The houses allocated NOT to receive ITENs and ITWS.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence of Plasmodium falciparum parasite.
Time Frame: Approximately 12 months post-installation, coinciding with the long rainy season.
|
Prevalence of plasmodium falciparum parasite measured by qPCR among residents over 6 months old in houses with ITENs & ITWS compared to houses without.
|
Approximately 12 months post-installation, coinciding with the long rainy season.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence of Plasmodium falciparum parasite.
Time Frame: Approximately 6 months post-installation, coinciding with the short rainy season.
|
Prevalence of plasmodium falciparum parasite in households' residents of over 6 months old with ITENs & ITWS compared to those without using qPCR analysis.
|
Approximately 6 months post-installation, coinciding with the short rainy season.
|
|
Clinical malaria.
Time Frame: Approximately 6 months and 12 months post-installation, coinciding with the rainy seasons.
|
The prevalence of clinical malaria cases defined by an axillary temperature of 37.5 degrees (fever) and positive mRDT in houses with ITENs and ITWS compared to the houses without.
|
Approximately 6 months and 12 months post-installation, coinciding with the rainy seasons.
|
|
The density of malaria vectors and nuisance mosquitoes density.
Time Frame: Approximately 6 months and 12 months post-installation, coinciding with the rainy seasons.
|
Indoor density of malaria vector and nuisance mosquitoes in houses with ITENs & ITWS compared to houses without measured using Centres for Disease Control (CDC) light traps.
|
Approximately 6 months and 12 months post-installation, coinciding with the rainy seasons.
|
|
ITENs & ITWS fabric cost
Time Frame: Baseline (During installation of ITENs & ITWS)
|
The number of metres of material applied to houses.
|
Baseline (During installation of ITENs & ITWS)
|
|
ITENS & ITWS time duration
Time Frame: Baseline (During installation of ITENs & ITWS)
|
Time in hours to install the intervention.
|
Baseline (During installation of ITENs & ITWS)
|
|
Adverse effects
Time Frame: Approximately one month post installation.
|
The number of participants with perceived adverse effects from ITENs and ITWS.
|
Approximately one month post installation.
|
|
Attrition
Time Frame: Appriximately 6 months and 12 months post installation.
|
Determination of the physical presence of ITENs and ITWS in the field.
|
Appriximately 6 months and 12 months post installation.
|
|
Fabric integrity
Time Frame: Appriximately 6 months and 12 months post installation.
|
Determination of the number of holes in ITENs and ITWS in the field.
|
Appriximately 6 months and 12 months post installation.
|
|
The induced mosquito mortality of ITENs and ITWs on the population of laboratory-reared mosquitoes.
Time Frame: Approximately 12 months post installation.
|
The bioefficacy (% induced mosquito mortality) of ITENs and ITWS after field use through WHO bioassays.
|
Approximately 12 months post installation.
|
|
Insecticide retainment
Time Frame: Appriximately 12 months post installation.
|
The retention of deltamethrin and PBO in grams per kg will be assessed through high performance liquid chromatography.
|
Appriximately 12 months post installation.
|
|
Use of ITENs and ITWS
Time Frame: Approximately 6 months and 12 months post installation.
|
Community opinions of ITENs and ITWS will be sought through questionnaires and Focus Group Discussions.
|
Approximately 6 months and 12 months post installation.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: John Bradley, PhD, London School of Hygiene and Tropical Medicine
Publications and helpful links
General Publications
- Gnanguenon V, Azondekon R, Oke-Agbo F, Beach R, Akogbeto M. Durability assessment results suggest a serviceable life of two, rather than three, years for the current long-lasting insecticidal (mosquito) net (LLIN) intervention in Benin. BMC Infect Dis. 2014 Feb 8;14:69. doi: 10.1186/1471-2334-14-69.
- Matiya DJ, Philbert AB, Kidima W, Matowo JJ. Dynamics and monitoring of insecticide resistance in malaria vectors across mainland Tanzania from 1997 to 2017: a systematic review. Malar J. 2019 Mar 26;18(1):102. doi: 10.1186/s12936-019-2738-6.
- Mboera LE, Mweya CN, Rumisha SF, Tungu PK, Stanley G, Makange MR, Misinzo G, De Nardo P, Vairo F, Oriyo NM. The Risk of Dengue Virus Transmission in Dar es Salaam, Tanzania during an Epidemic Period of 2014. PLoS Negl Trop Dis. 2016 Jan 26;10(1):e0004313. doi: 10.1371/journal.pntd.0004313. eCollection 2016 Jan.
- Mboma ZM, Overgaard HJ, Moore S, Bradley J, Moore J, Massue DJ, Kramer K, Lines J, Lorenz LM. Mosquito net coverage in years between mass distributions: a case study of Tanzania, 2013. Malar J. 2018 Mar 1;17(1):100. doi: 10.1186/s12936-018-2247-z.
- Gleave K, Lissenden N, Richardson M, Choi L, Ranson H. Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa. Cochrane Database Syst Rev. 2018 Nov 29;11(11):CD012776. doi: 10.1002/14651858.CD012776.pub2.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ITENs
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria,Falciparum
-
Medicines for Malaria VentureSwiss Tropical & Public Health Institute; Rinda Ubuzima, Rwanda; Swiss BioQuant; ACE ResearchNot yet recruitingMalaria | Malaria Infection | Malaria Prophylaxis | Malaria (Plasmodium Falciparum) | Malaria Falciparum | Malaria Parasitaemia | Malaria PreventionRwanda
-
Universidad Nacional de ColombiaSanofi Pasteur, a Sanofi CompanyCompleted
-
National Institute for Medical Research, TanzaniaWorld Health Organization; Muhimbili University of Health and Allied SciencesCompletedUncomplicated Falciparum MalariaTanzania
-
University of OxfordCompletedSevere Falciparum MalariaBangladesh
-
Heidelberg UniversityCompletedUncomplicated Falciparum MalariaBurkina Faso
-
Dafra PharmaCompletedMulti-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum MalariaPlasmodium Falciparum MalariaCameroon, Mali, Rwanda, Sudan
-
University of OxfordTerminatedP. Falciparum MalariaThailand
-
National Institute of Allergy and Infectious Diseases...CompletedAccute Falciparum MalariaMali
-
Medical University of ViennaInternational Centre for Diarrhoeal Disease Research, Bangladesh; Armed Forces...CompletedAzithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in BangladeshUncomplicated Falciparum MalariaBangladesh
-
Medecins Sans Frontieres, NetherlandsUniversity of Oxford; Mahidol University; Disease Control, Department of Health...UnknownUncomplicated Falciparum MalariaMyanmar
Clinical Trials on ITENs + ITWS
-
Rio de Janeiro State UniversityUniversidade Federal Fluminense; Rio de Janeiro State Research Supporting Foundation...RecruitingDepression | Quality of Life | Obesity | Anxiety Disorders | Heart Rate VariabilityBrazil